BR112017018319A2 - formulação e métodos para controlar o ciclo reprodutivo e a ovulação - Google Patents

formulação e métodos para controlar o ciclo reprodutivo e a ovulação

Info

Publication number
BR112017018319A2
BR112017018319A2 BR112017018319A BR112017018319A BR112017018319A2 BR 112017018319 A2 BR112017018319 A2 BR 112017018319A2 BR 112017018319 A BR112017018319 A BR 112017018319A BR 112017018319 A BR112017018319 A BR 112017018319A BR 112017018319 A2 BR112017018319 A2 BR 112017018319A2
Authority
BR
Brazil
Prior art keywords
ovulation
formulations
methods
controlling
female mammal
Prior art date
Application number
BR112017018319A
Other languages
English (en)
Inventor
Roberto Sammartino Daniel
Andrés Colman Juan
Original Assignee
Proinvet Innovations S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proinvet Innovations S A filed Critical Proinvet Innovations S A
Publication of BR112017018319A2 publication Critical patent/BR112017018319A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

as formulações de hormônios, unidades de dosagem, incluindo as formulações de hormônios, e métodos de uso se referem a uma formulação de liberação controlada, que inclui hormônios, por exemplo, progesterona. as formulações e os métodos são para controlar o ciclo de reprodução e/ou a ovulação de um mamífero do sexo feminino, por exemplo, para promover a ovulação em um mamífero do sexo feminino ou sincronizar a ovulação ou calor/estro de um grupo de mamíferos do sexo feminino. além disso, as formulações são para aumentar a probabilidade de que um mamífero do sexo feminino se torne prenhe, por exemplo, após a inseminação ou transferência de embrião. além disso, formulações são para a redução do período de anestro em um mamífero do sexo feminino.
BR112017018319A 2015-12-18 2016-12-16 formulação e métodos para controlar o ciclo reprodutivo e a ovulação BR112017018319A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2015/066863 WO2017105512A1 (en) 2015-12-18 2015-12-18 Formulations and methods for controlling the reproductive cycle and ovulation
PCT/US2016/067132 WO2017106618A1 (en) 2015-12-18 2016-12-16 Formulations and methods for controlling the reproductive cycle and ovulation

Publications (1)

Publication Number Publication Date
BR112017018319A2 true BR112017018319A2 (pt) 2018-04-17

Family

ID=59057228

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018319A BR112017018319A2 (pt) 2015-12-18 2016-12-16 formulação e métodos para controlar o ciclo reprodutivo e a ovulação

Country Status (14)

Country Link
US (1) US10898432B2 (pt)
EP (1) EP3389690B1 (pt)
CN (1) CN108367046B (pt)
AR (2) AR107067A1 (pt)
AU (1) AU2016369500A1 (pt)
BR (1) BR112017018319A2 (pt)
CL (1) CL2018001635A1 (pt)
CO (1) CO2018006041A2 (pt)
ES (1) ES2893121T3 (pt)
MX (1) MX2018007354A (pt)
NZ (1) NZ744338A (pt)
PE (1) PE20181290A1 (pt)
UY (1) UY37033A (pt)
WO (2) WO2017105512A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
CN111281877A (zh) * 2018-11-22 2020-06-16 南京诺瑞特医药科技有限公司 神经活性类固醇的新制剂
CN110215433A (zh) * 2019-07-16 2019-09-10 苏州素仕生物科技有限公司 一种氯前列醇注射液及其制备方法
US20230044690A1 (en) * 2019-12-23 2023-02-09 Augusta University Research Institute, Inc. Progesterone formulation to trigger ovulation and provide luteal phase support
CN111346054A (zh) * 2020-03-10 2020-06-30 上海图珐医药科技有限公司 一种黄体酮乳剂型注射剂及其制备方法
CN115137697A (zh) * 2021-08-17 2022-10-04 浙江科瑞特生物科技有限公司 一种d-氯前列醇钠注射液及其制备方法、应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599227A (en) 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6028057A (en) 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
EP1065936B1 (en) * 1998-03-23 2009-08-05 General Mills, Inc. Encapsulation of components into edible products
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
DE60121925T2 (de) 2000-03-22 2007-03-01 The Secretary Of State For Defence, Salisbury Arzneimittel zur verabreichung an schleimhäute
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
ATE371442T1 (de) 2001-10-12 2007-09-15 Elan Pharma Int Ltd Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
AU2003208679A1 (en) 2002-02-08 2003-09-02 Advanced Animal Technology Limited Control of a biological function
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20070104778A1 (en) * 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20090036384A1 (en) * 2005-12-02 2009-02-05 Parnell Laboratories (Aust) Pty Limited Increasing pregnancy rates
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
JP2010505819A (ja) * 2006-10-05 2010-02-25 パナセア バイオテック リミテッド デポ型注射剤組成物とその調製方法
MXPA06015172A (es) 2006-12-20 2009-04-17 Gonzalo Urbiola Verdejo Solucion inyectable de progesterona de liberacion prolongada para uso veterinario y proceso de obtencion del mismo.
CN101152186B (zh) 2007-09-05 2011-07-06 杭州平和安康医药科技有限公司 黄体酮注射液及其制备方法
CN101427993A (zh) * 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 前列腺素微乳凝胶制剂及其制备方法
WO2010085363A1 (en) * 2009-01-26 2010-07-29 Hal Witt Estrus synchronization preparations and effective cidr-less protocols
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
UY33103A (es) 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
CN101856361A (zh) 2010-06-08 2010-10-13 瓜州县龙兴畜牧产业发展有限公司 一种用于母牛发情调控的孕酮复合制剂
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
AR082266A1 (es) * 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CN103284955A (zh) 2012-03-02 2013-09-11 上海市计划生育科学研究所 长效孕激素缓释注射埋植剂及其制备方法
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
ES2869250T3 (es) * 2012-06-18 2021-10-25 Therapeuticsmd Inc Cápsula de estradiol soluble para inserción vaginal
CN103585103A (zh) 2012-08-15 2014-02-19 杭州伟智生物医药科技有限公司 一种含tpgs的性激素微纳米人体注射乳剂及其制备方法
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2017105512A1 (en) 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation

Also Published As

Publication number Publication date
CL2018001635A1 (es) 2018-08-17
CN108367046A (zh) 2018-08-03
EP3389690A1 (en) 2018-10-24
MX2018007354A (es) 2018-11-09
WO2017105512A1 (en) 2017-06-22
AR107067A1 (es) 2018-03-14
EP3389690B1 (en) 2021-07-07
AU2016369500A1 (en) 2018-06-07
PE20181290A1 (es) 2018-08-07
EP3389690A4 (en) 2019-08-28
NZ744338A (en) 2020-03-27
AR125357A2 (es) 2023-07-12
CO2018006041A2 (es) 2018-07-10
ES2893121T3 (es) 2022-02-08
US20180289614A1 (en) 2018-10-11
UY37033A (es) 2017-07-31
CN108367046B (zh) 2021-12-21
US10898432B2 (en) 2021-01-26
WO2017106618A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
BR112017018319A2 (pt) formulação e métodos para controlar o ciclo reprodutivo e a ovulação
BR112018070199A2 (pt) composição farmacêutica de hormônio esteroide
AR117670A2 (es) Modulador del receptor de andrógeno y sus usos
BR112018069877A2 (pt) composição farmacêutica de hormônio esteróide
BR112012026953A8 (pt) Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica
EP2421545A4 (en) METHOD AND DEVICE FOR SYNCHRONIZING THE BREWING TIME
BR112017002466A2 (pt) formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação
BR112018008549A2 (pt) composição de feromonia para estimular a reprodução em suínos femininos e métodos de uso
BR112015012453A8 (pt) métodos e usos para sincronizar o tempo de ovulação e de inseminação em uma leitoa
BR112017013521A2 (pt) terapia de antagonista do receptor de oxitocina na fase luteal para implantação e gravidez em mulheres sob tecnologias reprodutivas assistidas
BR112016010427A2 (pt) proteína para prevenir infecção por mycoplasma spp., composição para prevenir infecção por mycoplasma spp., vetor de expressão, e método para preparar antígeno solúvel
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
WO2016164460A3 (en) Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
CL2019003801A1 (es) Nuevas formulaciones orales de belinostato.
WO2019094292A8 (en) Compositions and methods of providing thyroid hormone or analogs thereof
BR112016022354A2 (pt) Aparelho de transferência e método de transferência
Aké-López et al. Effect of progestagen and dose of equine gonadotropin corionic on estrus sinchronization and pregnancy rate in pelibuey ewes following laparoscopic insemination
UY36168A (es) FORMULACIONES INTRAVAGINALES QUE COMPRENDEN GnRH
BR112021022860A2 (pt) Composições e métodos para aumentar o desempenho da reprodução em mamíferos não humanos com uso de hormônio luteinizante recombinante
Pfeifer et al. Efeito da progesterona injetável no desenvolvimento folicular em vacas de corte lactantes tratadas com estradiol e dispositivo de progesterona de baixa concentração
UA98347U (ru) Способ профилактики невынашивания беременности у женщин с наличием мужского и женского фактора бесплодия после экстракорпорального оплодотворения методом интрацитоплазматической инъекции сперматозоидов в яйцеклетку
AR112218A1 (es) Métodos de inyección única y formulación para inducir y controlar múltiples folículos ováricos en bovinos, caprinos, ovinos, camélidos y otros animales hembras
Labeur et al. Impact of cold exposure and shearing stress during pregnancy on lamb latency to bleat
UY35526A (es) Derivados de espiroindolina y composiciones farma céuticas de los mismos

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PROINVET INNOVATIONS S.A. (AR)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]